Related Experiment Video
Updated: Aug 7, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Prediabetes, Malignant Left Ventricular Hypertrophy, and Risk of Incident Heart Failure Among Hypertensive Adults
Arnaud D Kaze1, Stephen P Juraschek2, Jordana B Cohen3
1Division of Cardiology, Department of Medicine, Banner-University Medical Center Phoenix, The University of Arizona College of Medicine-Phoenix, Arizona, USA.
Insights
Prediabetes combined with malignant left ventricular hypertrophy (LVH) significantly increases heart failure (HF) risk in hypertensive adults. This combination, not prediabetes alone, identifies a high-risk group for targeted prevention.
Area of Science:
- Cardiology
- Endocrinology
- Preventive Medicine
Background:
- Prediabetes is prevalent in hypertensive individuals, but its independent impact on heart failure (HF) risk, especially with subclinical cardiac abnormalities, is not fully understood.
- Hypertension and prediabetes are significant risk factors for cardiovascular disease, necessitating a deeper understanding of their combined effects on HF development.
Purpose of the Study:
- To investigate the association between prediabetes, malignant left ventricular hypertrophy (LVH), and incident heart failure (HF) risk.
- To determine if prediabetes exacerbates HF risk in hypertensive adults with LVH, defined by subclinical myocardial injury or stress.
Main Methods:
- Prospective cohort analysis of 8,131 hypertensive adults without diabetes from the SPRINT trial.
- Left ventricular hypertrophy (LVH) assessed via Cornell voltage product; subclinical myocardial injury by troponin I levels; subclinical myocardial stress by NT-proBNP levels.
- Cox proportional hazards models used to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for HF events.
Main Results:
- A total of 115 HF events occurred during a median follow-up of 3.3 years.
- Hypertensive adults with both prediabetes and malignant LVH exhibited a 3.55-fold increased risk of HF compared to normoglycemic individuals without malignant LVH.
- Prediabetes combined with LVH and myocardial injury or stress showed HRs of 4.02 and 4.04, respectively; prediabetes alone did not significantly increase HF risk (HR: 1.24).
Conclusions:
- The coexistence of prediabetes and malignant LVH identifies a high-risk subgroup for heart failure among hypertensive adults.
- Integrating glycemic status, ECG-derived LVH, and cardiac biomarkers can improve HF risk stratification and guide preventive interventions.
Background:
Prediabetes is common among adults with hypertension, but its contribution to heart failure (HF) risk, particularly in the presence of subclinical myocardial abnormalities, remains uncertain.
Objectives:
The objective of the study was to assess whether prediabetes combined with malignant left ventricular hypertrophy (LVH)-defined as LVH accompanied by subclinical myocardial injury or stress-is associated with increased HF risk in hypertensive adults without diabetes.
Methods:
This prospective cohort analysis included 8,131 hypertensive adults without diabetes or prior HF from the SPRINT (Systolic Blood Pressure Intervention Trial). LVH was defined using the Cornell voltage product. Subclinical myocardial injury was defined as high-sensitivity cardiac troponin I ≥6 ng/L (men) or ≥4 ng/L (women), and subclinical myocardial stress as N-terminal pro-B-type natriuretic peptide ≥125 pg/mL. Cox proportional hazards models estimated adjusted HRs and 95% CIs for HF.
Results:
During a median 3.3-year follow-up, 115 HF events occurred. Compared with normoglycemic adults without malignant LVH, those with both prediabetes and malignant LVH had higher HF risk (adjusted HR: 3.55; 95% CI: 1.98-6.36). Similar patterns were observed for prediabetes with LVH plus myocardial injury (HR: 4.02; 95% CI: 2.21-7.30) or stress (HR: 4.04; 95% CI: 2.22-7.34). Prediabetes alone was not associated with HF (adjusted HR: 1.24; 95% CI: 0.80-1.91).
Conclusions:
Among hypertensive adults, the coexistence of prediabetes and malignant LVH identifies a subgroup at substantially elevated HF risk. Integrating glycemic status, ECG findings, and cardiac biomarkers may enhance HF risk stratification and inform preventive strategies.
Related Concept Videos
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure I: Introduction
Diabetes: Symptoms, Diagnosis, and Complications
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension I: Introduction
